JUBLINGREA Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,051 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹136 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jubilant Ingrevia reported stable Q3 FY26 results with revenue of Rs 1,151 crore and EBITDA flat QoQ at 13% despite challenging pricing environment across all three segments. While volumes grew ~9% YoY, lower pricing compressed margins—EBITDA declined 8% YoY to Rs 136 crore, and PAT fell to Rs 47 crore after Rs 13 crore exceptional charge from labor code amendments. On 9-month basis, EBITDA grew 8% to Rs 436 crore and PAT increased 8%, demonstrating resilience. Specialty chemicals sustained margins above 25% through mix improvement and cost initiatives, while the Nutrition segment saw highest B3 volumes in seven quarters. CDMO pipeline expanded to 100+ opportunities with peak revenue potential of Rs 3,500 crore; 16 wins confirmed with Rs 1,400 crore potential. Large agrochemical CDMO order remains on track for late March dispatch. Outlook for Q4 appears improving as pricing has bottomed out with early uptick visible in pyridine and B3. Key risks include persistent pricing pressure, Europe demand weakness, and execution timeline on CDMO ramp-up.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects improved performance in Q4 driven by pricing recovery in specialty chemicals and nutrition, partial recovery in acetate portfolio, and commencement of large CDMO dispatch.
- With new agro CDMO plant commissioning, multi-purpose Gajola facility construction underway, and 100+ pipeline opportunities, FY27 expected to see significant capacity utilization acceleration at ~50% utilized assets.
- Year-to-date capex of Rs 366 crore largely directed toward Bharuch CDMO/agro plant and Gajola multi-purpose facility; next fiscal year investment of approximately Rs 500 crore to be funded through internal accruals.
- Target to sustain EBITDA margins at minimum 25% in specialty chemicals through continued cost initiatives, improved product mix with higher fine chemicals/CDMO share, and pricing recovery.
Risks flagged
- Pricing declines in specialty chemicals (pyridine derivatives), nutrition (B3, choline), and chemical intermediates have offset volume gains. While management sees bottoming, no significant recovery materialized yet in Q3.
- European operations face weak demand and plant closures weighing on chemical intermediates segment. Rising raw material costs squeeze margins in oversupplied market.
- Large Rs 1,400 crore agrochemical CDMO order commencement was delayed from January to late March 2026; analyst questioned whether customer regulatory tightening or volume commitments could affect Jubilant's visibility—management declined to provide specifics citing confidentiality.
- EU FTA benefits (removal of 6-7% duties) contingent on agreement execution in early 2026; customer order patterns remained tentative during uncertainty period, and actual volume/pricing gains dependent on case-by-case negotiations.
Key quotes
- We have grown more than double digit in volume and mix for the specialty. Yeah. And the pricing has gone back in the high single digits. That's why our specialty has grown on a year-to-date basis.
- The hope is as soon as the pricing starts to come back you will see a meaningful jump in the absolute margins as well while we still maintain the percentage at least at 25% like we have done in the last five or six quarters.
- FY27 is like a pivotal year in which a lot of that capacity we are hoping to fill on the back of both confirmed orders which we have announced as part of our pipeline but also some of the new areas that we are working on.
Research modules